AIP
ITCI

Ameritas Investment Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ameritas Investment Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,484
Closed -$656K – 3255
2024
Q1 		$656K Hold
9,484
– – 0.02% 739
2023
Q4 		$679K Buy
9,484
+174
+2% +$10K 0.02% 715
2023
Q3 		$485K Buy
9,310
+1,572
+20% +$91.6K 0.02% 782
2023
Q2 		$490K Buy
7,738
+555
+8% +$34.6K 0.02% 770
2023
Q1 		$389K Hold
7,183
– – 0.02% 838
2022
Q4 		$349K Hold
7,183
– – 0.01% 869
2022
Q3 		$334K Buy
7,183
+312
+5% +$16.3K 0.02% 856
2022
Q2 		$392K Buy
6,871
+701
+11% +$39.7K 0.02% 818
2022
Q1 		$378K Buy
6,170
+600
+11% +$31.2K 0.01% 880
2021
Q4 		$292K Hold
5,570
– – 0.01% 1006
2021
Q3 		$208K Hold
5,570
– – 0.01% 1179
2021
Q2 		$227K Hold
5,570
– – 0.01% 1152
2021
Q1 		$189K Hold
5,570
– – 0.01% 1260
2020
Q4 		$177K Hold
5,570
– – 0.01% 1223
2020
Q3 		$143K Buy
5,570
+981
+21% +$22.4K 0.01% 1219
2020
Q2 		$118K Hold
4,589
– – 0.01% 1312
2020
Q1 		$71K Buy
4,589
+850
+23% +$18.5K ﹤0.01% 1462
2019
Q4 		$128K Hold
3,739
– – 0.01% 1366
2019
Q3 		$28K Hold
3,739
– – ﹤0.01% 2218
2019
Q2 		$49K Hold
3,739
– – ﹤0.01% 1926
2019
Q1 		$46K Hold
3,739
– – ﹤0.01% 1931
2018
Q4 		$43K Hold
3,739
– – ﹤0.01% 1905
2018
Q3 		$81K Sell
3,739
-450
-11% -$9.41K ﹤0.01% 1696
2018
Q2 		$74K Buy
4,189
+517
+14% +$10.5K ﹤0.01% 1750
2018
Q1 		$77K Hold
3,672
– – ﹤0.01% 1658
2017
Q4 		$53K Buy
3,672
+708
+24% +$10.9K ﹤0.01% 1897
2017
Q3 		$54K Hold
2,964
– – ﹤0.01% 1855
2017
Q2 		$37K Hold
2,964
– – ﹤0.01% 2100
2017
Q1 		$48K Buy
+2,964
New +$42.9K ﹤0.01% 1883

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's ITCI Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 9,484 shares — an estimated $656K sold.

Ameritas Investment Partners first reported a position in ITCI in Q1 2017 and held it in 29 quarters. The position peaked at $679K in Q4 2023. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • Ameritas Investment Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • Ameritas Investment Partners sold 9,484 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $656K.
  • Ameritas Investment Partners first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 29 quarters.
  • Ameritas Investment Partners's Intra-Cellular Therapies Inc. position peaked at $679K in Q4 2023.
  • 376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.